Dermatologists and longevity researchers are urging patients to stop short of injecting copper peptides, a compound that has moved from face serums to home syringes without a single published human study showing the injectable form is safe or effective.
The compound is GHK-Cu, a copper-bound string of three amino acids that has circulated in cosmetic products for decades. What changed is the route. People are now drawing the electric blue liquid into subcutaneous injections, often stacking it with other peptides marketed for tissue repair, and buying it from sellers who operate outside any regulatory system.
For households, the practical concern is not the ingredient itself. It is that a person can order an injectable vial online, administer it at home, and have no way to confirm what is inside the vial, how much of it there is, or whether it is sterile. Two risks appear by name in reporting by NPR: overloading the body with copper, and triggering a dangerous immune reaction.
The Shift from Serum to Syringe
Copper peptide creams and serums have been sold and studied for years. Topical GHK-Cu has been through human trials, and the dermatology view of it is not dismissive.
"The science behind this is very solid," said Dr. David Goldberg, director of cosmetic dermatology for the Schweiger Dermatology Group and a clinical professor at the Icahn School of Medicine at Mount Sinai in New York. He described the peptide as helping bolster collagen, which he called part of the scaffolding of the skin, and placed it roughly on par with other topical ingredients such as vitamin C and antioxidants.
That endorsement covers creams. It does not extend to needles. Goldberg said injecting could plausibly deliver more of the molecule, since it does not easily penetrate into deeper skin layers when applied on the surface, but he and other dermatologists are advising patients to hold off. He said he will not sleep well at night until the human studies are done.
Where the Human Evidence Stops
The controlled human research on GHK-Cu has focused almost entirely on skin and aesthetics, with smaller amounts on wound healing and hair growth. Those trials have generally been small and funded by the cosmetics industry.
Everything beyond skin sits in laboratory and animal work. In animal studies, the peptide sped wound healing and showed effects on organ repair, including fibrosis in the lungs. Dr. Warren Ladiges, a professor at the University of Washington School of Medicine who has studied the compound for years, has shown that it stimulates pathways associated with aging and eases some Alzheimer's symptoms in mouse models.
Ladiges is not hostile to the compound. He said he believes it could have a major role in helping enhance longevity, and that animal data suggest it is generally quite safe. He was blunt about the injections anyway.
"I wouldn't do that to myself," he said.
He also explained why the human trials may never arrive. GHK-Cu occurs naturally in the body, which makes it hard for a drug company to patent without creating a distinct version and paying for trials on it. In his assessment, federal approval is probably never coming.
Sourcing Is Where the Risk Concentrates
The sharpest concern in the reporting is not pharmacology. It is supply.
Most people injecting GHK-Cu are buying it from unregulated suppliers with no assurance of quality or dosage, according to Dr. Marisa Garshick of MDCS Dermatology. She said whether the product is even a copper peptide is a persistent worry.
"The stakes are much higher when you're injecting something," she said.
Clinicians are already seeing consequences. Erik Marks, a doctor of nursing practice who runs a wellness and longevity clinic near Seattle called Vitality Medical PNW, said most of his consultations on the compound involve patients who already bought it online, already injected it, and only then became worried. He described problems ranging from injection site irritation and infection to more serious effects on the liver, including patients whose liver enzymes and copper levels were elevated after injecting far too much without checking any lab work.
He noted an important limitation. In those cases, it is unclear whether the copper peptide, some other undisclosed substance, or an impurity is responsible. Marks does offer the compound in his own practice, sourced from a licensed compounding pharmacy, and said the topical versions work much better for skin and hair while injections tend to have minimal impact.
"People need to understand these peptides are not silver bullets to fix health," Marks said.
The cost dimension is easy to overlook. Injectable vials bought online are paid for out of pocket, and none of the follow-up that would make self-injection safer, such as liver panels or serum copper testing, comes bundled with the purchase. Patients typically discover they needed those tests only after something goes wrong.
Regulators Take Up the Question Again
The legal status is unsettled. Compounding pharmacies in the United States are not technically permitted to offer GHK-Cu for injection in humans, though federal officials have signaled that could change.
Earlier this summer, a panel advising the Food and Drug Administration recommended that the government reclassify about half a dozen of these wellness peptides. That FDA advisory panel on compounding is scheduled to meet again in February to review the evidence on GHK-Cu as an injectable, among other peptides. Until then, the product remains widely available on the gray market. The FDA maintains a list of bulk drug substances that may present significant safety risks in compounding.
Anyone already using an injectable version should speak with a clinician rather than simply continuing or stopping without guidance, particularly if they have not had liver or copper levels checked. Symptoms that warrant prompt medical attention include spreading redness, swelling or pus at an injection site, fever, unusual fatigue, or yellowing of the skin or eyes. Topical serums remain a separate product category with a longer safety record, and nothing in the current reporting suggests people should discard them.
Key Questions Answered
What is GHK-Cu? It is a naturally occurring copper complex of a three-amino-acid peptide, first isolated in the early 1970s by chemist Loren Pickart. Levels in human blood decline with age.
Is it an approved drug? No. It is not FDA-approved. Topical cosmetic versions have been sold for decades, but the injectable form has no approval.
Are the creams considered risky? The dermatologists quoted describe the topical evidence as solid and comparable to other established skin ingredients. The warnings in this reporting concern injections.
What are the named risks of injecting it? Overloading the body with copper and triggering a dangerous immune reaction. Clinicians also report injection site infections and elevated liver enzymes in people who injected on their own.
Why does the source of the product matter so much? Injectable formulations bought from unregulated online sellers carry no assurance of identity, dose, purity or sterility. A cream applied to skin and a substance injected under it carry very different consequences if contaminated.
Can a compounding pharmacy legally supply it for injection? Not under current rules, although federal officials have signaled the policy may change.
When will regulators revisit this? An FDA advisory panel is scheduled to review the evidence on injectable GHK-Cu in February.
